Prescient Therapeutics (ASX:PTX) has announced the expansion of its Phase 1b clinical study of PTX-200 and cytarabine in patients with relapsed and refractory acute myeloid leukemia. …
Prescient expands PTX-200 AML cohort following additional complete remission
May 10, 2022 Australian Biotech
Latest Video
New Stories
-
Anteris Technologies expands its medical advisory board
May 25, 2022 - - Australian Biotech -
Archer Materials secures Australian patent for quantum computing chip
May 25, 2022 - - Australian Biotech -
New clinical trial to test cancer drug in motor neuron disease
May 25, 2022 - - Latest News -
Australian Dental Association anticipates change in aged care
May 25, 2022 - - Other Health -
New plan to build a disability confident culture at Medibank
May 25, 2022 - - Other Health -
Bupa giving customers greater transparency and choice
May 25, 2022 - - Other Health -
US-based industry sets objectives for new trade alliance
May 25, 2022 - - Latest News